Evaluation of liver diseases in Iranian patients with primary antibody deficiencies

Introduction. Patients with primary antibody deficiency (PAD) can complicate with liver disease. This study was performed in order to study the prevalence and causes of hepatobiliary diseases in Iranian patients with PAD.Material and methods. Sixty-two patients with PAD were followed-up and signs an...

Full description

Bibliographic Details
Main Authors: Farzaneh Motamed, Asghar Aghamohammadi, Mahmoud Soltani, Mahboubeh Mansouri, Nima Rezaei, Shahram Teimourian, Nima Pouladi, Sina Abdollahzadeh, Nima Parvaneh
Format: Article
Language:English
Published: Elsevier 2009-07-01
Series:Annals of Hepatology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S166526811931765X
id doaj-15a3da2659884772b30ee0b567888399
record_format Article
spelling doaj-15a3da2659884772b30ee0b5678883992021-06-09T05:55:49ZengElsevierAnnals of Hepatology1665-26812009-07-0183196202Evaluation of liver diseases in Iranian patients with primary antibody deficienciesFarzaneh Motamed0Asghar Aghamohammadi1Mahmoud Soltani2Mahboubeh Mansouri3Nima Rezaei4Shahram Teimourian5Nima Pouladi6Sina Abdollahzadeh7Nima Parvaneh8Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran.Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran.; Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.; Correspondence and reprint requestPediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran.Mofid Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran.; Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.; Pasteur Institute of Iran, Tehran, Iran.Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.Students’ Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran.; Growth and Development Research Center, Tehran University of Medical Sciences, Tehran, Iran.Introduction. Patients with primary antibody deficiency (PAD) can complicate with liver disease. This study was performed in order to study the prevalence and causes of hepatobiliary diseases in Iranian patients with PAD.Material and methods. Sixty-two patients with PAD were followed-up and signs and symptoms of liver disease were recorded. All patients were screened for hepatitis C virus (HCV-RNA) and those patients with any sign of liver disease or gastrointestinal complaints were tested for Cryptosporidium parvum.Results. Clinical evidences of liver disease, including hepatomegaly, were documented in 22 patients (35.5%). Eight patients (13%) had clinical and/or laboratory criteria of chronic liver disease. Only one patient was HCV-RNA positive; he had stigmata of chronic liver disease and pathologic evidence of chronic active hepatitis with cirrhosis. Cryptosporidium parvum test was positive for one patient with hyper-IgM syndrome. In liver biopsy of patients with liver involvement, one had histological findings related to sclerosing cholangitis, and five had mild to moderate chronic active hepatitis with unknown reason.Conclusions. Chronic active hepatitis is the most common pathologic feature of liver injury in Iranian patients with PAD. Liver disease in PAD usually accompanies with other organ involvements and could increase the mortality of PAD. Whether this high rate of liver disease with unknown origin (75%) is the result of an unidentified hepatotropic virus or other mechanisms such as autoimmunity, is currently difficult to understand.http://www.sciencedirect.com/science/article/pii/S166526811931765XLiver diseasePrimary antibody deficiencyHCV infectionChronic active hepatitis
collection DOAJ
language English
format Article
sources DOAJ
author Farzaneh Motamed
Asghar Aghamohammadi
Mahmoud Soltani
Mahboubeh Mansouri
Nima Rezaei
Shahram Teimourian
Nima Pouladi
Sina Abdollahzadeh
Nima Parvaneh
spellingShingle Farzaneh Motamed
Asghar Aghamohammadi
Mahmoud Soltani
Mahboubeh Mansouri
Nima Rezaei
Shahram Teimourian
Nima Pouladi
Sina Abdollahzadeh
Nima Parvaneh
Evaluation of liver diseases in Iranian patients with primary antibody deficiencies
Annals of Hepatology
Liver disease
Primary antibody deficiency
HCV infection
Chronic active hepatitis
author_facet Farzaneh Motamed
Asghar Aghamohammadi
Mahmoud Soltani
Mahboubeh Mansouri
Nima Rezaei
Shahram Teimourian
Nima Pouladi
Sina Abdollahzadeh
Nima Parvaneh
author_sort Farzaneh Motamed
title Evaluation of liver diseases in Iranian patients with primary antibody deficiencies
title_short Evaluation of liver diseases in Iranian patients with primary antibody deficiencies
title_full Evaluation of liver diseases in Iranian patients with primary antibody deficiencies
title_fullStr Evaluation of liver diseases in Iranian patients with primary antibody deficiencies
title_full_unstemmed Evaluation of liver diseases in Iranian patients with primary antibody deficiencies
title_sort evaluation of liver diseases in iranian patients with primary antibody deficiencies
publisher Elsevier
series Annals of Hepatology
issn 1665-2681
publishDate 2009-07-01
description Introduction. Patients with primary antibody deficiency (PAD) can complicate with liver disease. This study was performed in order to study the prevalence and causes of hepatobiliary diseases in Iranian patients with PAD.Material and methods. Sixty-two patients with PAD were followed-up and signs and symptoms of liver disease were recorded. All patients were screened for hepatitis C virus (HCV-RNA) and those patients with any sign of liver disease or gastrointestinal complaints were tested for Cryptosporidium parvum.Results. Clinical evidences of liver disease, including hepatomegaly, were documented in 22 patients (35.5%). Eight patients (13%) had clinical and/or laboratory criteria of chronic liver disease. Only one patient was HCV-RNA positive; he had stigmata of chronic liver disease and pathologic evidence of chronic active hepatitis with cirrhosis. Cryptosporidium parvum test was positive for one patient with hyper-IgM syndrome. In liver biopsy of patients with liver involvement, one had histological findings related to sclerosing cholangitis, and five had mild to moderate chronic active hepatitis with unknown reason.Conclusions. Chronic active hepatitis is the most common pathologic feature of liver injury in Iranian patients with PAD. Liver disease in PAD usually accompanies with other organ involvements and could increase the mortality of PAD. Whether this high rate of liver disease with unknown origin (75%) is the result of an unidentified hepatotropic virus or other mechanisms such as autoimmunity, is currently difficult to understand.
topic Liver disease
Primary antibody deficiency
HCV infection
Chronic active hepatitis
url http://www.sciencedirect.com/science/article/pii/S166526811931765X
work_keys_str_mv AT farzanehmotamed evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
AT asgharaghamohammadi evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
AT mahmoudsoltani evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
AT mahboubehmansouri evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
AT nimarezaei evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
AT shahramteimourian evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
AT nimapouladi evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
AT sinaabdollahzadeh evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
AT nimaparvaneh evaluationofliverdiseasesiniranianpatientswithprimaryantibodydeficiencies
_version_ 1721388540337586176